{"id":"NCT01386125","sponsor":"Organon and Co","briefTitle":"A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) in the Treatment of Nasal Polyps (Protocol No. P05604)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2011-06-30","resultsPosted":"2013-12-19","lastUpdate":"2024-05-21"},"enrollment":748,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Nasal Polyps"],"interventions":[{"type":"DRUG","name":"Mometasone Furoate Nasal Spray (MFNS)","otherNames":[]},{"type":"DRUG","name":"Placebo for MFNS","otherNames":[]}],"arms":[{"label":"Mometasone Furoate Nasal Spray (MFNS)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the effectiveness and safety of MFNS in improving nasal congestion/obstruction and in reducing bilateral nasal polyps.","primaryOutcome":{"measure":"Change From Baseline in Congestion/Obstruction Score","timeFrame":"Baseline and Weeks 1-4","effectByArm":[{"arm":"MFNS","deltaMin":-0.56,"sd":0.03},{"arm":"Placebo","deltaMin":-0.42,"sd":0.03}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26575524"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":375},"commonTop":[]}}